February 6, 2014 | Israeli company Tiltan Pharma, which is developing a treatment for pancreatic cancer, has raised $1.5 million. The company will use the proceeds to complete its Phase II clinical trial of its metastatic pancreatic cancer treatment TL-118. Details about the source of the investment were not disclosed.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments